The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Neal Shore, MD, FACS, Carolina Urologic Research Center, discusses the ABLE-32 study on the use of nadofaragene firadenovec for intermediate-risk, BCG-unresponsive non-muscle invasive bladder cancer. He reviews the history of the treatment in high-risk disease, and the anticipated outcomes of ABLE-32.

(0:12) Nadofaragene for High-Risk Disease, Data of FDA Approval
(2:38) Differences of IR and HR NMIBC
(4:16) Nadofaragene's Mechanism of Action
(5:03) ABLE-32's Design and Anticipated Outcomes
(6:15) Potential Barriers During 5-Year Evaluation
(7:36) Next Steps for ABLE-32
Category
Urology
Be the first to comment

Up Next